Urology, GI & Women's Health Devices: Global Regulation & Registration

For every regulator below we answer the three questions device teams ask first: what class is my product, how long will registration take, and what will it cost. Every cost has two parts - the government fee, and our flat annual service fee per market - and you can model both in our pricing calculator.

What are urology, GI, and women's health devices?

Urology, gastrointestinal (GI), and women's health devices are the tools used to diagnose and treat conditions of the urinary tract and kidneys, the digestive tract, and the female reproductive system. The urology side spans urinary (Foley) catheters, ureteral stents, cystoscopes and ureteroscopes, lithotripsy systems, urodynamic equipment, and dialysis systems for kidney failure. The GI side adds endoscopes, GI stents, enteral feeding tubes, and hemostatic and closure devices. Women's health - increasingly marketed today under the "femtech" label - covers diagnostic ultrasound, colposcopes and hysteroscopes, intrauterine devices, pessaries, and surgical mesh.

Two boundaries matter before you classify anything. First, some products in this space are not devices at all in the regulatory sense: in the US, every marketed IUD - hormonal or copper - is regulated as a drug rather than a device, because copper IUDs are treated as new drugs under 21 CFR 310.502 for incorporating a heavy metal, while in the EU a copper IUD is a Class III medical device under MDR Rule 15 and a hormonal IUD is a medicinal product. Second, a wellness or period-tracking app on its own is usually not a regulated device, even when it is sold as women's health technology. Once you are genuinely dealing with a device, the catch is that every jurisdiction draws the classification line differently - the same indwelling catheter or implant can be a mid-risk device in one market and a high-risk implant requiring full premarket approval in another.

FDA regulation of urology and women's health devices (United States)

FDA regulates this category across the full risk spectrum. Most of the everyday hardware is Class II and clears through a 510(k); the high-risk implants are the exception and go the premarket approval (PMA) route.

• Classification. Urinary catheters, dialysis systems, ureteral stents, cystoscopes, GI endoscopes, and diagnostic ultrasound are generally Class II, cleared with a 510(k) against a predicate. Marketed IUDs - copper and hormonal alike - are regulated as drugs by CDER, not as devices (copper IUDs are new drugs under 21 CFR 310.502; only nonmedicated inert IUDs fall under the Class III device regulation at 21 CFR 884.5360, and none are marketed). Surgical mesh for transvaginal pelvic organ prolapse was reclassified to Class III after a difficult safety history that led FDA to halt US sales in 2019.
• Timeline. A 510(k) typically runs 3 to 9 months end to end including preparation and FDA interaction. A PMA for a Class III product such as an implantable transvaginal mesh should be planned as a multi-year program with clinical data. A Pre-Submission meeting adds a few weeks up front and routinely saves review cycles later.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses) plus US$11,423 per year in establishment registration; a PMA runs far higher. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Home and portable dialysis machines

Home and portable dialysis is one of the highest-demand topics in this category, and the regulatory picture is simpler than the shopping questions suggest. In the US, hemodialysis systems - including home and portable machines - are Class II devices cleared through the 510(k) pathway, with home-use clearances resting on a strong human-factors file and clinical performance data for lay use in the home. The registration government fee is the 510(k) fee above; it is separate from the machine's capital cost and from what a patient or payer ultimately pays, which is a reimbursement question rather than a registration one. For a manufacturer the task is the same everywhere: build the 510(k) or technical file once, prove home-use safety, then register market by market.

Start from our United States market page for the full FDA pathway.

EU MDR classification for urology and women's health devices

Under the Medical Device Regulation (EU 2017/745), classification is driven by how invasive a device is and how long it stays in the body, and a notified body sits in the middle of almost every timeline in this category.

• Classification. Short-term and diagnostic tools sit lower, and indwelling and long-term catheters and ureteral stents are typically Class IIb - but the implants that define this category sit at the top: surgical mesh is Class III under MDR Rule 8, and intrauterine and other implantable or long-term invasive contraceptive devices are Class III under Rule 15. Genuinely low-class devices are the minority here, and every IIb and III device needs notified body involvement.
• Timeline. Plan 12 to 18 months with a notified body for a first Class IIb certification, and longer for Class III, driven by notified body capacity and the maturity of your technical documentation and clinical evaluation.
• Cost. There is no central government fee; the money goes to the notified body - typically EUR 30,000 to EUR 70,000 across a first Class IIa/IIb certification cycle, higher for Class III - plus annual surveillance and the cost of building MDR-grade documentation. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

Notified body strategy should shape your EU plan early; see the European Union market page for the MDR route.

Urology and women's health device registration in Brazil and Latin America (ANVISA)

Brazil is the anchor of any Latin American strategy. ANVISA classifies devices into risk Classes I to IV on the IMDRF model under RDC 751, and Mexico's COFEPRIS is the region's second gate. Both require a local representative - we act as Brazil Registration Holder without taking control of your registration.

• Classification. Class I-II devices - many catheters, basic instruments, and diagnostic tools - qualify for the streamlined notificacao route, while Class III-IV products such as implants and long-term invasive devices require full registro with deeper technical and clinical evidence.
• Timeline. Notification is typically a matter of weeks; Class III-IV registration plans for 6 to 12 months. In Mexico, COFEPRIS runs 6 to 12 months, faster where reliance on FDA or CE approvals applies.
• Cost. ANVISA government fees: R$1,406 to notify a Class I-II product; Class III-IV family registration runs R$8,510-19,856, plus a one-time international B-GMP certification of R$72,805 where required. COFEPRIS charges MX$16,499 to MX$30,798 per product by class, and Colombia's INVIMA starts at COP 3,898,330. Our registration service starts at US$2,000 per year (US$3,000 for high-risk classes) across the region.

Start with the Brazil market page; labeling, instructions for use, and submissions are prepared natively in Portuguese and Spanish.

Urology and women's health device registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas manufacturers enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a good FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN - Malaysia, Thailand, Indonesia, Vietnam, the Philippines - where reliance-friendly frameworks make each additional market incremental. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry - local type testing and the longest timelines - so treat it as its own program when the business case justifies it, not as a default stop.

• Classification. Singapore's HSA uses risk Classes A through D, and ASEAN members track the same IMDRF-style model. Japan classifies against JMDN codes through PMDA, Korea's MFDS uses Classes I-IV, and China's NMPA places most of this category in Class II or III, with long-term implants and contraceptive devices at the top end.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the same dossier. Japan plans for 9 to 14 months via PMDA, Korea 6 to 12 months including KGMP, and China 12 to 24 months including type testing.
• Cost. Singapore's fees are light: an SGD 560 application plus SGD 2,010-6,250 evaluation by class; Malaysia runs MYR 500 plus MYR 750-3,000, and Thailand THB 3,100-21,000 with a THB 53,000 expert review where required. China's NMPA fees for an imported Class II-III device run roughly RMB 210,000-310,000 before type testing, and Japan's PMDA review fees start around JPY 1 million. Our registration service starts at US$2,000 per year across Singapore and ASEAN; China, Japan, and Korea are quoted flat per market on the same model.

One well-built reference dossier does most of the region's work. See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Urology and women's health device registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing regions in our portfolio, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work when the dossier is assembled correctly. SFDA regulates this category on the IMDRF model and requires a local Authorized Representative.

• Classification. SFDA classifies devices into risk Classes A through D, mirroring your reference-market class in most cases; the UAE's MOHAP and other MENA authorities lean on the reference approval's classification.
• Timeline. With a reference approval in hand, SFDA marketing authorization typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest - generally a few thousand US dollars' equivalent per authority - so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote SFDA and MENA programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages; we run the wider region under one program.

Evidence, quality system, and lifecycle

This category lives or dies on clinical and biological evidence. Long-term invasive and implantable devices carry the heaviest expectations: biocompatibility to ISO 10993 for anything in prolonged tissue or urinary-tract contact, sterilization validation for single-use catheters and instruments, validated reprocessing instructions - cleaning plus high-level disinfection or sterilization - for reusable scopes such as cystoscopes, ureteroscopes, and endoscopes, which FDA expects to see validated in the 510(k) under its reprocessing guidance and watches closely post-market after the duodenoscope and urological-endoscope safety communications, and clinical evidence that scales with risk - modest for a well-precedented Class II catheter, substantial for a Class III implant or contraceptive device. We set up ISO 13485 and FDA QMSR processes, plan clinical evidence once for reuse across FDA, EU MDR, and APAC submissions, and treat post-market surveillance as a first-class deliverable rather than an afterthought; the surgical-mesh history is a permanent reminder that vigilance and real-world follow-up decide whether a device stays on the market. For connected products such as home dialysis systems and remote-monitoring wearables, we also maintain cybersecurity documentation that satisfies FDA and EU MDR expectations.

One program, every major market

A global urology and women's health program is a sequencing problem: pick the anchor market, build the clinical and technical file once, and reuse classification analyses, evidence, and QMS artifacts everywhere else. We run the full program from a single team - strategy, submissions, in-country representation, and post-market maintenance - with transparent government fees and timelines in our pricing calculator.